VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued on Sunday. The brokerage set a “sell” rating on the stock.

A number of other equities research analysts have also weighed in on the company. D. Boral Capital restated a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a research report on Tuesday, December 10th. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Stock Performance

NYSE:VNRX opened at $0.61 on Friday. VolitionRx has a fifty-two week low of $0.43 and a fifty-two week high of $1.23. The company has a market cap of $56.81 million, a price-to-earnings ratio of -1.70 and a beta of 1.17. The stock has a fifty day moving average price of $0.67 and a 200-day moving average price of $0.66.

Insider Activity at VolitionRx

In other news, CEO Cameron John Reynolds purchased 139,811 shares of the company’s stock in a transaction on Monday, December 9th. The stock was purchased at an average price of $0.57 per share, with a total value of $79,692.27. Following the completion of the purchase, the chief executive officer now directly owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Guy Archibald Innes purchased 174,764 shares of the business’s stock in a transaction on Monday, December 9th. The shares were acquired at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the transaction, the director now owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have bought 358,266 shares of company stock worth $204,212. Company insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC lifted its position in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the quarter. Geode Capital Management LLC owned approximately 0.79% of VolitionRx worth $439,000 at the end of the most recent quarter. 8.09% of the stock is owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.